Literature DB >> 23564765

In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer.

Regina Arantes-Rodrigues1, Aura Colaço, Rosário Pinto-Leite, Paula A Oliveira.   

Abstract

Several drugs have shown in vitro and in vivo pharmacological activity against urinary bladder cancer. This review aims at compiling the different drugs evaluated in in vitro and in vivo models of urinary bladder cancer and to review the advantages and limitations of both types of models, as well as the different methodologies applied for evaluating antineoplastic drug activity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23564765

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  10 in total

1.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

2.  Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.

Authors:  Yoriko Yamashita-Kashima; Keigo Yorozu; Takaaki Fujimura; Natsumi Kawasaki; Mitsue Kurasawa; Shigeki Yoshiura; Naoki Harada; Osamu Kondoh; Yasushi Yoshimura
Journal:  Int J Hematol       Date:  2022-03-18       Impact factor: 2.490

Review 3.  Applications of Polymers for Organ-on-Chip Technology in Urology.

Authors:  Bianca Galateanu; Ariana Hudita; Elena Iuliana Biru; Horia Iovu; Catalin Zaharia; Eliza Simsensohn; Marieta Costache; Razvan-Cosmin Petca; Viorel Jinga
Journal:  Polymers (Basel)       Date:  2022-04-20       Impact factor: 4.967

4.  Implementation of Humane Endpoints in a Urinary Bladder Carcinogenesis Study in Rats.

Authors:  Mónica Oliveira; Elisabete Nascimento-Gonçalves; Jessica Silva; Paula A Oliveira; Rita Ferreira; Luís Antunes; Regina Arantes-Rodrigues; Ana I Faustino-Rocha
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

5.  Studying humane endpoints in a rat model of mammary carcinogenesis.

Authors:  Ana I Faustino-Rocha; Mário Ginja; Rita Ferreira; Paula A Oliveira
Journal:  Iran J Basic Med Sci       Date:  2019-06       Impact factor: 2.699

6.  Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.

Authors:  Amira Abugomaa; Mohamed Elbadawy; Megumi Yamanaka; Yuta Goto; Kimika Hayashi; Takashi Mori; Tsuyoshi Uchide; Daigo Azakami; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Risako Yamashita; Mio Kobayashi; Hideyuki Yamawaki; Yuta Shinohara; Masahiro Kaneda; Tatsuya Usui; Kazuaki Sasaki
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

Review 7.  An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders.

Authors:  Anushka Bhargava; Ana M Sandoval Castellanos; Sonali Shah; Ke Ning
Journal:  Interface Focus       Date:  2022-08-12       Impact factor: 4.661

8.  Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.

Authors:  Regina Arantes-Rodrigues; Rosário Pinto-Leite; Lio Fidalgo-Gonçalves; Carlos Palmeira; Lúcio Santos; Aura Colaço; Paula Oliveira
Journal:  Biomed Res Int       Date:  2013-11-28       Impact factor: 3.411

9.  Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody.

Authors:  Tadanobu Nagaya; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Deborah W Knapp; Sophia N Karagiannis; Judit Fazekas-Singer; Peter L Choyke; Amy K LeBlanc; Erika Jensen-Jarolim; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2018-04-10

10.  Decursin inhibits tumor progression in head and neck squamous cell carcinoma by downregulating CXCR7 expression in vitro.

Authors:  Mina Joo; Jong Beom Heo; Solbi Kim; Nayoung Kim; Heung Jin Jeon; Yueun An; Gyu-Yong Song; Jin-Man Kim; Hyo Jin Lee
Journal:  Oncol Rep       Date:  2021-12-27       Impact factor: 3.906
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.